Literature DB >> 34531944

Novel Substituted 1,6-Naphthyridines as CDK 5 Inhibitors for Treating Kidney Diseases.

Ram W Sabnis1.   

Abstract

Entities:  

Year:  2021        PMID： 34531944      PMCID： PMC8436244          DOI： 10.1021/acsmedchemlett.1c00424

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.632


× No keyword cloud information.
  6 in total

Review 1.  Cyclin-dependent Kinases as Emerging Targets for Developing Novel Antiviral Therapeutics.

Authors:  Lucia Gutierrez-Chamorro; Eudald Felip; Ifeanyi Jude Ezeonwumelu; Mireia Margelí; Ester Ballana
Journal:  Trends Microbiol       Date:  2021-02-19       Impact factor: 17.079

Review 2.  Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases.

Authors:  Zhouling Xie; Xiaoxiao Yang; Yajun Duan; Jihong Han; Chenzhong Liao
Journal:  J Med Chem       Date:  2021-01-22       Impact factor: 7.446

Review 3.  Transcriptional cyclin-dependent kinases as the mediators of inflammation-a review.

Authors:  Vaishnavi Sundar; Sanjana Vimal; M S Sai Mithlesh; Anupam Dutta; Ramasamy Tamizhselvi; Venkatraman Manickam
Journal:  Gene       Date:  2020-10-05       Impact factor: 3.688

Review 4.  A comprehensive insight on the recent development of Cyclic Dependent Kinase inhibitors as anticancer agents.

Authors:  Brilliant N Marak; Jayanta Dowarah; Laldingluaia Khiangte; Ved Prakash Singh
Journal:  Eur J Med Chem       Date:  2020-07-15       Impact factor: 6.514

Review 5.  Pharmacological relevance of CDK inhibitors in Alzheimer's disease.

Authors:  Nishtha Malhotra; Rohan Gupta; Pravir Kumar
Journal:  Neurochem Int       Date:  2021-06-25       Impact factor: 3.921

Review 6.  New Insights into CDK Regulators: Novel Opportunities for Cancer Therapy.

Authors:  Marina Bury; Benjamin Le Calvé; Gerardo Ferbeyre; Volker Blank; Frédéric Lessard
Journal:  Trends Cell Biol       Date:  2021-03-03       Impact factor: 20.808
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.